Silverarc Capital Management, LLC Tcr2 Therapeutics Inc. Transaction History

Silverarc Capital Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$8.44 - $18.35 $1.59 Million - $3.45 Million	-188,142 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$16.41 - $24.71 $541,480 - $815,355	32,997 Added 21.27%	188,142 $3.09 Million
Q1 2021 May 18, 2021	BUY	$20.38 - $34.07 $390,175 - $652,270	19,145 Added 14.08%	155,145 $3.43 Million
Q4 2020 Feb 16, 2021	BUY	$19.0 - $32.63 $2.58 Million - $4.44 Million	136,000 New	136,000 $4.21 Million

Ticker TCRR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,606,400
Description
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical tria...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.